美银证券研究报告指,药明生物(02269.HK) 发盈喜,料2025年收入按年增长16.7%至218亿元人民币(下同),符合该行预期,受惠于破纪录的新增项目数量,以及服务范围扩展,尤其在BsAb和ADC平台方面。毛利率按年扩张5个百分点至46%,好过该行预期,主要因产能利用率提升,以及精益运营管理系统(WBS)推动效率改善。净利润及归属股东净利润分别为57亿及49亿元,按年增长45.3%及...
Source Link美银证券研究报告指,药明生物(02269.HK) 发盈喜,料2025年收入按年增长16.7%至218亿元人民币(下同),符合该行预期,受惠于破纪录的新增项目数量,以及服务范围扩展,尤其在BsAb和ADC平台方面。毛利率按年扩张5个百分点至46%,好过该行预期,主要因产能利用率提升,以及精益运营管理系统(WBS)推动效率改善。净利润及归属股东净利润分别为57亿及49亿元,按年增长45.3%及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.